Last reviewed · How we verify

Fentanyl-Morphine

Seoul National University Hospital · FDA-approved active Small molecule

This is a combination of two opioid agonists that bind to mu-opioid receptors in the central nervous system to produce analgesia and sedation.

This is a combination of two opioid agonists that bind to mu-opioid receptors in the central nervous system to produce analgesia and sedation. Used for Acute postoperative pain, Severe acute pain requiring opioid analgesia.

At a glance

Generic nameFentanyl-Morphine
SponsorSeoul National University Hospital
Drug classOpioid agonist combination
TargetMu-opioid receptor (OPRM1)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Fentanyl is a potent synthetic opioid agonist, while morphine is a natural opioid alkaloid; both work by activating mu-opioid receptors to modulate pain perception and produce analgesia. The combination may be used to optimize pain control through complementary pharmacokinetic profiles, with fentanyl providing rapid onset and morphine providing sustained duration. This dual-agent approach is typically employed in acute or perioperative pain management settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: